| [1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018 [J]. CA Cancer J Clin, 2018, 68(1): 7-30.
|
| [2] |
Vatandoost N, Ghanbari J, Mojaver M, et al. Early detection of colorectal cancer: from conventional methods to novel biomarkers [J]. J Cancer Res Clin Oncol. 2016, 142(2):341-351.
|
| [3] |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015 [J]. CA Cancer J Clin, 2016, 66(2):115-132.
|
| [4] |
Song L, Jia J, Peng X, et al. The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis [J]. Scientific Reports, 2017, 7(1): 3032.
|
| [5] |
Yan S, Liu Z, Yu S, et al. Diagnostic value of methylated Septin9 for colorectal cancer screening: A meta-analysis [J]. Medical Science Monitor International Medical Journal of Experimental & Clinical Research, 2016, 22: 3409-3418.
|
| [6] |
Sandrock K, Bartsch I, Bläser S, et al. Characterization of human septin interactions [J]. Biological Chemistry, 2011, 392(8-9): 751-761.
|
| [7] |
Oliva P, Maha EZ, Trimble WS. Uncovering the roles of Septins in Cilia [J]. Frontiers in Cell and Developmental Biology, 2017, 5: 36.
|
| [8] |
Russell SEH, Hall PA. Septin genomics: a road less travelled [J]. Biological Chemistry, 2011, 392(8-9)
|
| [9] |
Kojima K, Sakai I, Hasegawa A, et al. FLJ10849, a septin family gene, fuses MLL in a novel leukemia cell line CNLBC1 derived from chronic neutrophilic leukemia in transformation with t(4;11)(q21;q23) [J]. LEUKEMIA, 2004, 18(5): 998-1005.
|
| [10] |
Connolly D, Yang Z, Castaldi M, et al. Septin 9 isoform expression, localization and epigenetic changes during human and mouse breast cancer progression [J]. Breast Cancer Research, 2011, 13(4): R76.
|
| [11] |
Kim DS, Hubbard SL, Peraud A, et al. Analysis of mammalian Septin expression in human malignant brain tumors [J]. Neoplasia, 2004, 6(2): 168-178.
|
| [12] |
Behrouz Sharif S, Hashemzadeh S, Mousavi Ardehaie R, et al. Detection of aberrant methylated SEPT9 and NTRK3 genes in sporadic colorectal cancer patients as a potential diagnostic biomarker [J]. Oncol Lett, 2016, 12(6): 5335-5343.
|
| [13] |
Wasserkort R, Kalmar A, Valcz G, et al. Aberrant septin 9 DNA methylation in colorectal cancer is restricted to a single CpG island [J]. BMC Cancer, 2013, 13(1): 398.
|
| [14] |
Tóth Kinga, Ferenc S, Kalmár Alexandra, et al. Detection of methylated SEPT9 in plasma Is a reliable screening method for both left-and right-sided colon cancers [J]. PLoS ONE, 2012, 7(9): e46000.
|
| [15] |
Wu D, Zhou G, Jin P, et al. Detection of colorectal cancer using a simplified SEPT9 gene methylation assay is a reliable method for opportunistic screening [J]. J Mol Diagn, 2016, 18(4): 535-545.
|
| [16] |
Song L, Li Y, Jia J, et al. Algorithm optimization in methylation detection with multiple RT-qPCR [J]. PLoS One, 2016, 11(11): e0163333.
|
| [17] |
Lofton-Day C, Model F, Devos T, et al. DNA Methylation Biomarkers for Blood-Based Colorectal Cancer Screening [J]. Clinical Chemistry, 2008, 54(2): 414-423.
|
| [18] |
Lee HS, Hwang SM, Kim TS, et al. Circulating methylated Septin 9 nucleic acid in the plasma of patients with gastrointestinal cancer in the stomach and colon [J]. Transl Oncol, 2013, 6(3): 290-296.
|
| [19] |
Lin JS, Piper MA, Perdue LA, et al. Screening for colorectal cancer: updated evidence report and systematic review for the US preventive services task force [J]. JAMA, 2016, 315(23): 2576-2594.
|
| [20] |
Issa IA, Noureddine M. Colorectal cancer screening: An updated review of the available options [J]. World J Gastroenterol, 2017, 23(28): 5086-5096.
|
| [21] |
Rex DK, Bond JH, Winawer S,et al. Quality in the technical performance of colonoscopy and the continuous quality improvement process for colonoscopy: recommendations of the U.S. Multi-Society Task Force on Colorectal Cancer [J]. Am J Gastroenterol, 2002, 97(6): 1296-1308.
|
| [22] |
Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators for colonoscopy and the risk of interval cancer [J]. N Engl J Med, 2010, 362(19): 1795-1803.
|
| [23] |
Lieberman D. A call to action-measuring the quality of colonoscopy [J]. N Engl J Med, 2006, 355(24): 2588-2589.
|
| [24] |
Eisen GM, Dominitz JA, Baron TH, et al. Complications of colonoscopy [J]. Gastrointest Endosc, 2003, 57: 441-445.
|
| [25] |
Carmona FJ, Azuara D, Berenguer-Llergo A, et al. DNA methylation biomarkers for noninvasive diagnosis of colorectal cancer [J]. Cancer Prev Res (Phila), 2013, 6(7): 656-665.
|
| [26] |
Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies [J]. BMJ, 2014, 348: g2467.
|
| [27] |
Scholefield JH, Moss SM, Mangham CM, et al. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up [J]. Gut, 2012, 61(7): 1036-1040.
|
| [28] |
Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer [J]. Br J Surg, 2008, 95(8): 1029-1036.
|
| [29] |
Young GP, Symonds EL, Allison JE, et al. Advances in fecal occult blood tests: the FIT revolution [J]. Dig Dis Sci, 2015, 60(3): 609-622.
|
| [30] |
Bretthauer M. Colorectal cancer screening [J]. J Intern Med, 2011, 270(2): 87-98.
|
| [31] |
Lee JK, Liles EG, Bent S, et al. Accuracy of fecal immunochemical tests for colorectal cancer [J]. Annals of Internal Medicine, 2014, 160(3): 171-181.
|
| [32] |
Fraser CG, Halloran SP, Allison JE, et al. Making colorectal cancer screening FITTER for purpose with quantitative faecal immunochemical tests for haemoglobin (FIT) [J]. Clin Chem Lab Med, 2013, 51(11): 2065-2067.
|
| [33] |
Wild N, Andres H，Rollinger W, et al. A combination of serum markers for the early detection of colorectal cancer [J]. Clinical Cancer Research, 2010, 16(24): 6111-6121.
|
| [34] |
Chen JS, Chen KT, Fan WC, et al. Combined analysis of survivin autoantibody and carcinoembryonic antigen biomarkers for improved detection of colorectal cancer [J]. Clin Chem Lab Med, 2010, 48(5): 719-725.
|
| [35] |
Yu H, Son GM, Joh YG. The clinical significance of preoperative serum levels of carbohydrate antigen 19-9 in colorectal cancer [J]. J Korean Surg Soc, 2013, 84(4): 231-237.
|
| [36] |
Adler A, Geiger S, Keil A, et al. Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany [J]. BMC Gastroenterol, 2014, 14(1): 183.
|
| [37] |
Hong-Bing FU, Wei-Min W. The application of combined defection of serum tumor markers levels of patients with colon cancer [J]. Chinese Journal of Clinicians, 2012, 6(17): 5087-5090.
|
| [38] |
Zhang Y, Yang J, Li H, et al. Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis [J]. Int J Clin Exp Med, 2015, 8(7): 11683-11691.
|
| [39] |
Luka de Vos, Heidrun Gevensleben, Andreas Schröck, et al. Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients [J]. Clin Epigenetics, 2017, 9(1): 125.
|
| [40] |
Dutruel C, Bergmann F, Rooman I, et al. Early epigenetic downregulation of WNK2 kinase during pancreatic ductal adenocarcinoma development [J]. Oncogene, 2013, 33(26): 3401-3410.
|
| [41] |
Laird PW. The power and the promise of DNA methylation markers [J]. Nat Rev Cancer, 2003, 3(4): 253-266.
|
| [42] |
Liggett TE, Melnikov A, Yi Q, et al. Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors [J]. Gynecol Oncol, 2011, 120(1): 113-120.
|
| [43] |
Zhu H, Bhagatwala J, Huang Y, et al. Race/Ethnicity-Specific Association of Vitamin D and Global DNA Methylation: Cross-Sectional and Interventional Findings [J]. PLoS One, 2016, 11(4): e0152849.
|
| [44] |
Zhang M, He Y, Zhang X, et al. A pooled analysis of the diagnostic efficacy of plasmic methylated septin-9 as a novel biomarker for colorectal cancer [J]. Biomed Rep, 2017, 7(4): 353-360.
|
| [45] |
Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylatedSEPT9in plasma for detection of asymptomatic colorectal cancer [J]. Gut, 2014, 63(2): 317-325.
|
| [46] |
Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins [J]. Proc Natl Acad Sci U S A, 2005, 102(30): 10604-10609.
|
| [47] |
Keating ST, El-Osta A. Epigenetics and metabolism [J]. Circ Res, 2015, 116(4): 715-736.
|
| [48] |
Mai-Britt W, Hans J, Torben F, et al. Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case-control study [J]. BMC Cancer, 2015, 15(1): 819.
|
| [49] |
He N, Song L, Kang Q, et al. The Pathological Features of Colorectal Cancer Determine the Detection Performance on Blood ctDNA [J]. Technol Cancer Res Treat, 2018, 17 : 1533033818791794.
|